Int. J. Neonatal Screen. 2018, 4(4), 37; https://doi.org/10.3390/ijns4040037
Neonatal Screening for Sickle Cell Disease in Belgium for More than 20 Years: An Experience for Comprehensive Care Improvement
Béatrice Gulbis 1,*, Phu-Quoc Lê 2, Olivier Ketelslegers 3, Marie-Françoise Dresse 4, Anne-Sophie Adam 1, Frédéric Cotton 1, François Boemer 5
, Vincent Bours 5, Jean-Marc Minon 3 and Alina Ferster 2
, Vincent Bours 5, Jean-Marc Minon 3 and Alina Ferster 2
1
Department of Clinical Chemistry, LHUB-ULB, Université Libre de Bruxelles (ULB) 322, Rue Haute, 1000 Brussels, Belgium
2
Department of Hemato-Oncology Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles (ULB) 15, av. J.J. Crocq, 1020 Brussels, Belgium
3
Department of Laboratory Medicine CHR de la Citadelle, 1, Boulevard de la 12ème Ligne, 4000 Liège, Belgium
4
Department of Pediatric, University Hospital Liège, CHR de la Citadelle, 1, Boulevard de la 12ème Ligne, 4000 Liège, Belgium
5
Department of Human Genetics CHU Sart Tilman, Université de Liège (ULg) Domaine Universitaire du Sart Tilmant Bâtiment 35-B, 4000 Liège, Belgium
*
Author to whom correspondence should be addressed.
Received: 7 October 2018 / Revised: 15 November 2018 / Accepted: 20 November 2018 / Published: 27 November 2018
(This article belongs to the Special Issue Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies)
Abstract
Our previous results reported that compared to sickle cell patients who were not screened at birth, those who benefited from it had a lower incidence of a first bacteremia and a reduced number and days of hospitalizations. In this context, this article reviews the Belgian experience on neonatal screening for sickle cell disease (SCD). It gives an update on the two regional neonatal screening programs for SCD in Belgium and their impact on initiatives to improve clinical care for sickle cell patients. Neonatal screening in Brussels and Liège Regions began in 1994 and 2002, respectively. Compiled results for the 2009 to 2017 period demonstrated a birth prevalence of sickle cell disorder above 1:2000. In parallel, to improve clinical care, (1) a committee of health care providers dedicated to non-malignant hematological diseases has been created within the Belgian Haematology Society; (2) a clinical registry was implemented in 2008 and has been updated in 2018; (3) a plan of action has been proposed to the Belgian national health authority. To date, neonatal screening is not integrated into the respective Belgian regional neonatal screening programs, the ongoing initiatives in Brussels and Liège Regions are not any further funded and better management of the disease through the implementation of specific actions is not yet perceived as a public health priority in Belgium. View Full-Text
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Gulbis, B.; Lê, P.-Q.; Ketelslegers, O.; Dresse, M.-F.; Adam, A.-S.; Cotton, F.; Boemer, F.; Bours, V.; Minon, J.-M.; Ferster, A. Neonatal Screening for Sickle Cell Disease in Belgium for More than 20 Years: An Experience for Comprehensive Care Improvement. Int. J. Neonatal Screen. 2018, 4, 37.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Article Metrics
Comments
[Return to top]
Int. J. Neonatal Screen.
EISSN 2409-515X
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert